Rhythm Biosciences (ASX:RHY): ColoSTAT Blood Testing and 2026 Commercial Milestones

Aditi Sarkar

14 October 2026 12:25 AM AEDT

Rhythm Biosciences (ASX:RHY): ColoSTAT Blood Testing and 2026 Commercial Milestones

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

ColoSTAT measures five protein biomarkers to assess the likelihood of colorectal cancer in symptomatic patients.
Clinical laboratory accreditation in March 2026 supported the test's introduction into an accredited testing service.
The ColoSTAT Access Program enrolled its first participating physician in February 2026.
Rhythm introduced an enhanced geneType colorectal cancer risk assessment test in January 2026.
A company-announced October 2026 health-economic study examined possible reductions in colonoscopy demand.

Rhythm Biosciences Limited (ASX:RHY) develops blood-based cancer detection and risk assessment technologies, including its ColoSTAT colorectal cancer test and geneType genetic risk assessment services. Its 2026 disclosures describe progress in laboratory accreditation, clinical introduction and distribution arrangements, and their clinical use.

ColoSTAT measures a panel of five protein biomarkers associated with colorectal cancer. The test is intended to help assess symptomatic patients rather than independently confirm a cancer diagnosis. Rhythm Biosciences (ASX:RHY) has positioned the blood test as an additional tool in a clinical pathway where doctors consider symptoms, clinical findings and further investigation.

Accreditation and the First Clinical Deployment

On 9 March 2026, Rhythm Biosciences (ASX:RHY) announced that ColoSTAT had been included in the accredited scope of its Parkville laboratory under ISO 15189:2022. The accreditation concerns laboratory quality and technical competence; it should not be confused with unrestricted regulatory authorisation across all markets.

An earlier announcement dated 11 February 2026 confirmed the first participating physician in the ColoSTAT Access Program. The controlled rollout was designed to introduce the service into clinical practice and gather information on patient pathways, laboratory logistics and adoption. The company subsequently reported its first clinical test sale in its March-quarter update issued in April 2026.

Clinical Evidence and the geneType Portfolio

In January 2026, the company announced peer-reviewed results for its first-generation ColoSTAT test, reporting 81.3% sensitivity and 91% specificity in the evaluated study. Sensitivity describes the proportion of affected patients correctly identified; specificity describes the proportion without the condition correctly classified. These figures reflect the stated study setting and do not guarantee identical performance in every clinical population.

Rhythm Biosciences (ASX:RHY) also released an enhanced geneType colorectal cancer risk assessment test on 14 January 2026. Unlike ColoSTAT, geneType combines genetic information with clinical and lifestyle factors to estimate risk and help inform screening discussions. The separate products address different questions: existing disease likelihood in a symptomatic setting versus an individual’s future risk profile.

Commercial Pathways and 2026 Developments

Rhythm Biosciences (ASX:RHY) disclosed agreements during 2026 involving test manufacturing, laboratory services and distribution. In March, it announced a supply and distribution agreement for its geneType portfolio with an initial focus on the Philippines. These arrangements establish commercial pathways, although signed agreements alone do not establish realised sales volumes or recurring profitability.

On 7 October 2026, the company reported findings from an independent health-economic modelling study concerning ColoSTAT in symptomatic patient triage. The study considered potential reductions in public-hospital colonoscopies if the test were incorporated into selected referral pathways. Its estimates are modelled scenarios, not observed changes in hospital activity.

Operating Considerations

For an emerging diagnostics business, uptake depends on clinician engagement, clinical evidence, laboratory capacity, reimbursement arrangements and regulatory requirements in each market. Rhythm Biosciences (ASX:RHY) also faces the costs of expanding testing operations and the risk that commercial adoption proceeds more slowly than planned. Published clinical performance should be interpreted within the specific validation population and intended test use.

Key Insights

Rhythm Biosciences (ASX:RHY) reported identifiable steps during 2026: accredited ColoSTAT testing, initial physician participation, enhanced geneType risk assessment and new commercial arrangements. The distinction between technical validation, clinical adoption and financial performance remains central. Its disclosures establish activity and early deployment milestones without proving the eventual scale of routine use or sustained revenue.

FAQs

Q: What is ColoSTAT?

A:It is a blood-based test measuring five protein biomarkers to assess colorectal cancer likelihood in symptomatic patients.

Q: What happened to ColoSTAT in March 2026?

A:The company announced that the test joined the accredited scope of its Parkville laboratory under ISO 15189:2022.

Q: Is ColoSTAT the same as geneType?

A:No. ColoSTAT assesses disease likelihood using proteins, while geneType uses genetic and other information for risk assessment.

Q: Did the company report clinical use during 2026?

A:Yes. It announced its first physician participant in February and a first clinical test sale in its March-quarter update.

Q: What did the October economic study establish?

A:It modelled possible effects on colonoscopy referrals; it did not measure reductions already achieved.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.